---
document_datetime: 2023-09-21 17:51:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/bondronat-epar-procedural-steps-taken-authorisation_en.pdf
document_name: bondronat-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.349199
conversion_datetime: 2025-12-28 18:42:19.035025
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Boehringer Mannheim GmbH submitted on 21 April 1995 an application for Marketing Authorisation to the EMEA for Bondronat ampoules, through the centralised procedure, in accordance with  Article  6  of  Council  Regulation  (EEC)  No.  2309/93.  After  agreement  by  the  CPMP  on 17 May 1995, this medicinal product is referred to List B in the Annex of the Council Regulation EEC No 2309/93, indent 7 as it contains a new active substance.

The Rapporteur and Co-Rapporteur appointed by the CPMP,  were:

Rapporteur:

Dr. Gorm Jensen

Co-Rapporteur:

Dr. Heribert Pittner

## Licensing status:

The product was not licensed in any country inside or outside the EEC at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The Rapporteur's Assessment Report was circulated to all CPMP Members on 21 July 1995. The Co-Rapporteur's Assessment Report was circulated to all CPMP Members on 11 July 1995.
- During the September CPMP meeting a draft consolidated list of questions was adopted and circulated  for  comments  by  22  September  1995.  The  final  consolidated  list  of  questions  was sent to the Company on 28 September 1995.
- The company submitted their responses to the consolidated list of questions on 20 November 1995.
- The Rapporteur circulated the comments on the company's responses to the list of questions to all CPMP Members on 22 December 1995.
- The  CPMP  during  its  meeting  of  13-15  February  1996,  in  the  light  of  the  current  scientific standards,  issued  a  positive  Opinion  for  granting  a  Marketing  Authorisation  to  Bondronat concentrate for solution for infusion on 14 February 1996.
- On 25 June 1996 the European Commission adopted a favourable Decision on the granting of a Marketing Authorisation for Bondronat.

II